


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A compound comprising the formula:

(I)




wherein:

R_1 is a polymeric residue;


Y_1 is O, S or NR_4 ;

M is O, S or NR_5 ;

E_1 is



$E_{2,4}$ are independently H, E_1 or



(a) is zero or one;

(m) is zero or a positive integer;



(n) and (p) are independently 0 or a positive integer;

$Y_{2,3}$ are independently O, S or NR_{10} ;

R_{2-10} are independently selected from the group consisting of hydrogen,

C_{1-6} alkyls, C_{3-12} branched alkyls, C_{3-8} cycloalkyls, C_{1-6} substituted alkyls, C_{3-8} substituted cycloalkyls, aryls, substituted aryls, aralkyls, C_{1-6} heteroalkyls, substituted C_{1-6} hetero-alkyls, C_{1-6} alkoxy, phenoxy and C_{1-6} heteroalkoxy;


D_1 and D_2 are independently OH,



or a terminal branching group;

wherein (v) and (t) are independently 0 or a positive integer up to about 6;

J is NR_{12} or



L_1 and L_2 are independently selected bifunctional linkers;

$\text{Y}_{4,7}$ are independently selected from the group consisting of O, S and NR_{14} , NR_{17} ;

R_{11-17} are independently selected from the group consisting of hydrogen, C_{1-6} alkyls,

C₃₋₁₂ branched alkyls, C₃₋₈ cycloalkyls, C₁₋₆ substituted alkyls, C₃₋₈ substituted cycloalkyls, aryls, substituted aryls, aralkyls, C₁₋₆ heteroalkyls, substituted C₁₋₆ heteroalkyls, C₁₋₆ alkoxy, phenoxy and C₁₋₆ heteroalkoxy;


Ar is a moiety which when included in Formula (I) forms a multi-substituted aromatic hydrocarbon or a multi-substituted heterocyclic group;

B₁ and B₂ are independently selected from the group consisting of leaving groups, OH, residues of hydroxyl-containing moieties or amine-containing moieties;


provided that E_{2,4} are not all H and

D₁ and D₂ are both not OH.


2. (Original) The compound of claim 1, wherein R₁ further comprises a capping group A, selected from the group consisting of hydrogen, NH₂, OH, CO₂H, C₁₋₆ moieties and



3. (Original) A compound of claim 2, comprising the formula:




4. (Currently Amended) The compound of claim 1, wherein said terminal branching group comprises the formula:




wherein

E₃₅ is



E₃₆₋₃₈ are independently H, E₃₅ or




(n) and (p) are independently 0 or a positive integer;

Y₂₋₃ are independently O, S or NR₁₀;

R₆₋₁₀ are independently selected from the group consisting of hydrogen, C₁₋₆ alkyls, C₃₋₁₂ branched alkyls, C₃₋₈ cycloalkyls, C₁₋₆ substituted alkyls, C₃₋₈ substituted cycloalkyls, aryls, substituted aryls, aralkyls, C₁₋₆ heteroalkyls, substituted C₁₋₆ hetero-alkyls, C₁₋₆ alkoxy, phenoxy and C₁₋₆ heteroalkoxy;

D'₁ and D'₂ are independently OH,



wherein (v) and (t) are independently 0 or a positive integer up to about 6;

L_1 and L_2 are independently selected bifunctional linkers;


Y_{4-7} are independently selected from the group consisting of O, S and NR_{17} , NR_{17} ;

R_{11-17} , R_{17-17} are independently selected from the group consisting of hydrogen, C_{1-6} alkyls, C_{3-12} branched alkyls, C_{3-8} cycloalkyls, C_{1-6} substituted alkyls, C_{3-8} substituted cycloalkyls, aryls, substituted aryls, aralkyls, C_{1-6} heteroalkyls, substituted C_{1-6} hetero-alkyls, C_{1-6} alkoxy, phenoxy and C_{1-6} heteroalkoxy;


B₁ and B₂ are independently selected from the group consisting of leaving groups, OH, residues of hydroxyl-containing moieties or amine-containing moieties;

$$\begin{array}{c} \text{R}_7 \\ | \\ \text{---} \text{C} \text{---} \text{C} \text{---} \text{D}''_1 \\ | \\ \text{R}_6 \end{array} \quad \begin{array}{c} \text{Y}_2 \\ || \\ \text{C} \end{array} \quad n$$
$$\begin{array}{c} \text{R}_9 \\ | \\ \text{---C---} \\ | \\ \text{R}_8 \end{array} \begin{array}{c} \text{Y}_3 \\ || \\ \text{C} \end{array} \text{---D}''_2$$

D''_1 and D''_2 are independently OH,



or




wherein at least one of D'_1 , D'_2 , D''_1 , and D''_2 is not OH.

5. (Previously amended) The compound of claim 3, wherein Y_1 is O.
6. (Original) The compound of claim 1, wherein R_1 comprises a polyalkylene oxide residue.
7. (Original) The compound of claim 6, wherein R_1 comprises a polyethylene glycol residue.
8. (Original) The compound of claim 3, wherein R_1 comprises a polyethylene glycol residue.
9. (Original) The compound of claim 6, wherein R_1 is selected from the group consisting of
 - $\text{---C(=Y}_6\text{)---(CH}_2\text{)}_f\text{---O---(CH}_2\text{CH}_2\text{O)}_x\text{---A}_1$,
 - $\text{---C(=Y}_6\text{)---Y}_7\text{---(CH}_2\text{)}_f\text{---O---(CH}_2\text{CH}_2\text{O)}_x\text{---A}_1$,
 - $\text{---C(=Y}_6\text{)---NR}_{23}\text{---(CH}_2\text{)}_f\text{---O---(CH}_2\text{CH}_2\text{O)}_x\text{---A}_1$,
 - $\text{---(CR}_{24}\text{R}_{25})_e\text{---O---(CH}_2\text{)}_f\text{---O---(CH}_2\text{CH}_2\text{O)}_x\text{---A}_1$,
 - $\text{---NR}_{23}\text{---(CH}_2\text{)}_f\text{---O---(CH}_2\text{CH}_2\text{O)}_x\text{---A}_1$,
 - $\text{---C(=Y}_6\text{)---(CH}_2\text{)}_f\text{---O---(CH}_2\text{CH}_2\text{O)}_x\text{---(CH}_2\text{)}_f\text{---C(=Y}_6\text{)---}$,
 - $\text{---C(=Y}_6\text{)---Y}_7\text{---(CH}_2\text{)}_f\text{---O---(CH}_2\text{CH}_2\text{O)}_x\text{---(CH}_2\text{)}_f\text{---Y}_7\text{---C(=Y}_6\text{)---}$,
 - $\text{---C(=Y}_6\text{)---NR}_{23}\text{---(CH}_2\text{)}_f\text{---O---(CH}_2\text{CH}_2\text{O)}_x\text{---(CH}_2\text{)}_f\text{---NR}_{23}\text{---C(=Y}_6\text{)---}$,
 - $\text{---(CR}_{24}\text{R}_{25})_e\text{---O---(CH}_2\text{)}_f\text{---O---(CH}_2\text{CH}_2\text{O)}_x\text{---(CH}_2\text{)}_f\text{---O---(CR}_{24}\text{R}_{25})_e\text{---}$, and
 - $\text{---NR}_{23}\text{---(CH}_2\text{)}_f\text{---O---(CH}_2\text{CH}_2\text{O)}_x\text{---(CH}_2\text{)}_f\text{---NR}_{23}\text{---}$


A is a capping group.

-
- The chemical structure represents a symmetrical polyimide, labeled as Formula 1. It consists of two identical repeating units connected by a central linkage. Each repeating unit features a central nitrogen atom (N) bonded to two carbonyl groups (C=O). The carbonyl groups are part of a five-membered imide ring, with the nitrogen atom also bonded to two carbonyl groups (C=O). The carbonyl groups are further substituted with a group D₁ and a group Y₂. The central nitrogen atom is also bonded to two carbonyl groups (C=O), which are further substituted with a group D₁ and a group Y₂. The central nitrogen atom is also bonded to two carbonyl groups (C=O), which are further substituted with a group D₁ and a group Y₂. The central nitrogen atom is also bonded to two carbonyl groups (C=O), which are further substituted with a group D₁ and a group Y₂.

14. (Original) The compound of claim 13, wherein D_1 is




15. (Original) The compound of claim 13, wherein D_1 is








16. (Original) The compound of claim 1, wherein L_1 is $(CH_2CH_2O)_2$.

17. (Original) The compound of claim 1, wherein L_2 is selected from the group consisting of $-CH_2-$, $-CH(CH_3)-$, $-CH_2C(O)NHCH(CH_3)-$, $-(CH_2)_2-$, $-CH_2C(O)NHCH_2-$, $-(CH_2)_2-NH-$, $-(CH_2)_2-NH-C(O)(CH_2)_2NH-$ and $-CH_2C(O)NHCH(CH_2CH(CH_3)_2)-$.


18. (Original) A compound of claim 1, selected from the group consisting of:







wherein R₁ is a PEG residue and D is selected from the group consisting of:




where B is a residue of an amine or a hydroxyl-containing drug.

19. (Original) A compound of claim 18, wherein B is a residue of a member of the group consisting of: daunorubicin, doxorubicin; *p*-aminoaniline mustard, melphalan, Ara-C (cytosine arabinoside), leucine-Ara-C, and gemcitabine

20. (Original) A method of treatment, comprising administering to a mammal in need of such treatment an effective amount of a compound of claim 1, wherein D₁ is a residue of a biologically active moiety.

21. (Original) A method of treatment, comprising administering to a mammal in need of such treatment an effective amount of a compound of claim 18.


22. (Original) The compound of claim 1, wherein Ar comprises the formula:



wherein R₁₁ and R₁₈₋₂₀ are individually selected from the group consisting of hydrogen, C₁₋₆ alkyls, C₃₋₁₂ branched alkyls, C₃₋₈ cycloalkyls, C₁₋₆ substituted alkyls, C₃₋₈ substituted cycloalkyls, aryls, substituted aryls, aralkyls, C₁₋₆ heteroalkyls, substituted C₁₋₆ hetero-alkyls, C₁₋₆ alkoxy, phenoxy and C₁₋₆ heteroalkoxy.

23. (Original) The compound of claim 22, wherein R₁₁ and R₁₈₋₂₀ are each H or CH₃.


24. (Previously amended) A method of preparing a polymer conjugate, comprising:
reacting a compound of the formula (VIII):



wherein

(v) and (t) are independently 0 or a positive integer up to about 6;

J is NR_{12} or



L_1 and L_2 are independently selected bifunctional linkers;


$\text{Y}_{4,5}$ are independently selected from the group consisting of O, S and NR_{17} ;

$\text{R}_{11,17}$ are independently selected from the group consisting of hydrogen, C_{1-6} alkyls, C_{3-12} branched alkyls, C_{3-8} cycloalkyls, C_{1-6} substituted alkyls, C_{3-8} substituted cycloalkyls, aryls, substituted aryls, aralkyls, C_{1-6} heteroalkyls, substituted C_{1-6} hetero-alkyls, C_{1-6} alkoxy, phenoxy and C_{1-6} heteroalkoxy;


Ar is a moiety which when included in Formula (I) forms a multi-substituted aromatic hydrocarbon or a multi-substituted heterocyclic group; and

B'_1 is a residue of a hydroxyl- or an amine-containing moiety;


with a compound of the formula (IX):



wherein



$E_{6,8}$ are independently H, E_5 or



D_3 and D_4 are independently OH, a leaving group which is capable of reacting with an unprotected amine or hydroxyl or a terminal branching group;

R_1 is a polymeric residue;

Y_1 is O, S or NR_4 ;

M is O, S or NR_5 ;

(a) is zero or one;

(m) is 0 or a positive integer;

(n) and (p) are independently 0 or a positive integer;

Y_{2-3} are independently O, S or NR_{10} ; and

R_{2-10} are independently selected from the group consisting of hydrogen, C_{1-6} alkyls, C_{3-12} branched alkyls, C_{3-8} cycloalkyls, C_{1-6} substituted alkyls, C_{3-8} substituted cycloalkyls, aryls, substituted aryls, aralkyls, C_{1-6} heteroalkyls, substituted C_{1-6} hetero-alkyls, C_{1-6} alkoxy, phenoxy and C_{1-6} heteroalkoxy;

provided that $E_{6,8}$ are not all H;

under conditions sufficient to cause a polymeric conjugate to be formed.